

**S1 Table.** Clinical characteristics according to cutoff values determined by ROC analysis

Characteristic	SUVmax < 12.7 (n=22)	SUVmax ≥ 12.7 (n=15)	p-val ue	TMTV < 302 (n=11)	TMTV ≥ 302 (n=26)	p-val e	TLG < 890 (n=11)	TLG ≥ 890 (n=26)	p-val e
Age (range)	22.5 (12-53)	22 (16-75)	0.394	34.5 (15-66)	26 (12-75)	0.272	34 (15-66)	20 (12-75)	0.051
Male sex	15 (68.2)	14 (93.3)	0.072	8 (72.7)	21 (80.8)	0.592	9 (81.8)	20 (76.9)	0.744
Ann Arbor stage			0.415			0.496			0.368
I	2 (9.1)	1 (6.7)		1 (9.1)	2 (7.7)		2 (18.2)	1 (3.8)	
II	1 (4.5)	1 (6.7)		2 (18.2)	2 (7.7)		1 (9.1)	2 (7.7)	
III	-	2 (13.3)						1 (3.8)	
IV	19 (86.4)	11 (73.3)		8 (72.7)	22 (84.6)		8 (72.7)	22 (84.6)	
IPI			<b>0.05</b>			0.292			0.076
0-2	16 (72.7)	6 (40.0)		8 (72.7)	14 (53.8)		20 (69.0)	26 (56.5)	
3-5	6 (27.3)	9 (60.0)		3 (27.3)	12 (46.2)		9 (31.0)	20 (43.5)	
B symptoms	6 (27.2)	1 (6.7)	0.117	2 (18.2)	5 (19.2)	0.903	2 (18.2)	5 (19.2)	0.903
ECOG ≥ 2	3 (13.6)	4 (26.7)	0.327	0	7 (26.9)	0.059	7 (24.1)	18 (39.1)	0.372
Bone marrow involvement	16 (72.7)	9 (60.0)	0.423	8 (72.7)	17 (65.4)	0.667	8 (72.7)	17 (65.4)	0.667
CNS involvement	2 (9.1)	3 (20.0)	0.405	1 (9.1)	4 (15.4)	0.654	1 (9.1)	4 (15.4)	0.654
Extra-nodal involvement ≥ 2 sites	9 (40.9)	11 (73.3)	0.055	2 (27.3)	17 (65.4)	<b>0.036</b>	10 (34.5)	14 (30.4)	<b>0.005</b>
Bulky mass in	9 (40.9)	8 (53.3)	0.463	4 (36.4%)	13 (50.0)	0.453	4 (36.4)	13 (50.0)	0.453

mediastinum									
β2 microglobulin (mg/L)	1.64 (0.15-4.68)	2.00 (0.40-4.84)	0.395	1.63 (0.40-3.58)	1.92 (0.99-4.84)	0.225	1.57 (0.60-2.36)	2.16 (0.40-4.84)	0.103
Creatinine (μmol/L)	61 (45-100)	70 (49-100)	0.159	63 (45-100)	65.5 (46-99)	0.790	62 (45-100)	71 (46-100)	0.653
Albumin (g/L)	41.3 (32.5-52.7)	43.3 (32.1-49.7)	0.300	44.5 (32.5-52.7)	41.3 (32.1-49.4)	<b>0.046</b>	42.9 (32.5-52.7)	41.6 (32.1-49.7)	0.595
LDH (U/L)	188.5 (90-1,679)	276 (120-1407)	0.216	184 (119-491)	253.5 (90-1679)	0.245	184 (119-491)	260.5 (90-1,679)	0.126
Hb (g/L)	122 (80-155)	144 (103-171)	<b>0.026</b>	141 (98-171)	125 (80-161)	0.435	127 (98-149)	127.5 (80-171)	0.690
PLT (×10 <sup>9</sup> /L)	202.5 (38-434)	241 (24-370)	0.781	210 (102-434)	232.5 (24-403)	0.790	190 (102-434)	241 (24-403)	0.388
Transplantation	7 (31.8%)	3 (20.0)	0.427	2 (18.2)	8 (30.8)	0.431	1 (9.1)	9(34.6)	0.110
Treatment regimen			0.943			0.501			0.501
Hyper-CVAD/MA	10 (45.5)	7 (46.7)		6 (54.5)	11 (42.3)		6 (54.5)	11 (42.3)	
BFM-90	12 (54.5)	8 (53.5)		5 (45.5)	15 (57.5)		5 (45.5)	15 (57.5)	

Values are presented as number (%) or median (range). CNS, central nervous system; ECOG, Eastern Cooperative Oncology Group; Hb, hemoglobin; Hyper-CVAD/MA, cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with high-dose methotrexate and cytarabine; LDH, lactate dehydrogenase; PLT, platelet; ROC, receiver-operating characteristic; SUVmax, standardized uptake value; TLG, total lesion glycolysis; TMTV, total metabolic tumor volume.